ZA974041B - Preparation and prevention of fibrotic lesions - Google Patents

Preparation and prevention of fibrotic lesions

Info

Publication number
ZA974041B
ZA974041B ZA974041A ZA974041A ZA974041B ZA 974041 B ZA974041 B ZA 974041B ZA 974041 A ZA974041 A ZA 974041A ZA 974041 A ZA974041 A ZA 974041A ZA 974041 B ZA974041 B ZA 974041B
Authority
ZA
South Africa
Prior art keywords
prevention
preparation
fibrotic lesions
fibrotic
lesions
Prior art date
Application number
ZA974041A
Other languages
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Publication of ZA974041B publication Critical patent/ZA974041B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ZA974041A 1996-05-09 1997-05-09 Preparation and prevention of fibrotic lesions ZA974041B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/647,006 US5716632A (en) 1989-11-22 1996-05-09 Compositions and methods for reparation and prevention of fibrotic lesions

Publications (1)

Publication Number Publication Date
ZA974041B true ZA974041B (en) 1998-11-09

Family

ID=24595333

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA974041A ZA974041B (en) 1996-05-09 1997-05-09 Preparation and prevention of fibrotic lesions

Country Status (11)

Country Link
US (1) US5716632A (fr)
EP (1) EP0902680A4 (fr)
JP (1) JP2000510467A (fr)
KR (1) KR20000010676A (fr)
AU (1) AU725637B2 (fr)
CA (1) CA2253919A1 (fr)
IL (1) IL126891A0 (fr)
NO (1) NO985197D0 (fr)
TR (1) TR199802273T2 (fr)
WO (1) WO1997041830A1 (fr)
ZA (1) ZA974041B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
WO1999047140A1 (fr) * 1998-03-17 1999-09-23 Margolin Solomon B Compositions et methodes topiques antiseptiques
DE69810518D1 (de) 1998-09-18 2003-02-06 Mepha Ag Aesch Topisch verabreichbare alkyl-, phenyl-pyridone-arzneimittel
DE60029246D1 (de) * 2000-01-24 2006-08-17 Solomon B Margolin Behandlung von brustkarzinomen, astrozytomen, melanomen und verwandten tumoren
DE10053870A1 (de) * 2000-10-31 2002-05-08 Burchardt Elmar Reinhold Procollagen (III)-Propeptide und verwandte Substanzen zur Behandlung von fibrotischen Erkrankungen
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
AU2003258305A1 (en) * 2002-08-28 2004-03-19 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
TW200418516A (en) * 2003-02-21 2004-10-01 Shionogi & Co Droplet dispersed ointment
EP1599171A2 (fr) * 2003-02-28 2005-11-30 Intermune, Inc. Therapie combinee servant a traiter une infection par un alphavirus et une fibrose hepatique
EP2390262A1 (fr) 2003-05-16 2011-11-30 Intermune, Inc. Ligands de récepteur de chimiokine synthétique et leurs procédés d'utilisation
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
EP2407470A3 (fr) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Acylsulfonamides et acides carboxyliques macrocycliques utilisés en tant qu'inhibiteurs de la réplication du virus de l'hépatite C
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005047256A1 (fr) * 2003-11-14 2005-05-26 Shanghai Genomics, Inc. Derives de pyridone, et utilisation correspondante
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CA2576030A1 (fr) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
AU2006244072B2 (en) * 2005-05-10 2012-09-20 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
BRPI0613962A2 (pt) 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
AU2006303955A1 (en) * 2005-10-11 2007-04-26 Intermune, Inc. Inhibitors of viral replication
KR101124070B1 (ko) * 2006-06-05 2012-04-12 제논 파마슈티칼스 인크. 유기 화합물
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008100867A2 (fr) * 2007-02-12 2008-08-21 Intermune, Inc. Nouveaux inhibiteurs de réplication du virus de l'hépatite c
CN101472588A (zh) * 2007-04-27 2009-07-01 达瑞科技投资有限公司 5－甲基－1－(取代苯基)－2－(1H)吡啶酮化合物作为抗炎药物和α－肿瘤坏死因子(TNF－α)阻断剂的应用
NZ581606A (en) 2007-05-03 2012-06-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
AU2008251425A1 (en) * 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US9029385B2 (en) * 2007-10-26 2015-05-12 Ganesh Raghu Compositions and methods for treating fibroproliferative disorders
US8093210B2 (en) * 2008-03-07 2012-01-10 Solanan, Inc. Treatment of sepsis with 5-ethyl-1-phenyl-2(1H)-pyridone
US8304413B2 (en) * 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN102216321A (zh) 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
KR20110114684A (ko) * 2009-01-26 2011-10-19 인터뮨, 인크. 급성 심근 경색 및 연관된 질환을 치료하는 방법
WO2010135972A1 (fr) 2009-05-25 2010-12-02 中南大学 Procédés de préparation et utilisations de composés de 1-(aryl substitué)-5-trifluorométhyl-2-(1h)-pyridone et de leurs sels
WO2010135976A1 (fr) 2009-05-25 2010-12-02 中南大学 Composés de 1-(benzyl substitué)-5-trifluorométhyl-2-(1h)-pyridone et de leurs sels, leurs procédés de préparation et leur utilisation
CN102741270B (zh) 2009-09-28 2015-07-22 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2824432C (fr) * 2011-01-31 2021-10-19 Genoa Pharmaceuticals, Inc. Composes analogues de pyridone et de pirfenidone en aerosol, et leurs utilisations
WO2012107831A1 (fr) 2011-02-11 2012-08-16 Signa S.A. De C.V. Procédé de fabrication d'un composé de pyridone, 5-éthyl-1-phényl-2-(1h)-pyridone, et ses intermédiaires
CA2819967C (fr) 2012-08-31 2016-03-22 Intermune, Inc. Utilisation de pirfenidone en simultanee avec du ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
EP3126362B1 (fr) 2014-04-02 2022-01-12 Intermune, Inc. Pyridinones anti-fibrotiques
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
JP2020517638A (ja) * 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
CN114716365B (zh) * 2022-01-04 2024-03-01 大连理工大学 一类n-取代苯基-2-吡啶酮化合物或其可药用盐在治疗肺纤维化中的应用
CN114805333A (zh) * 2022-05-09 2022-07-29 大连理工大学 一种主链含噁嗪和Cardo结构的双马来酰亚胺及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (fr) * 1972-12-18 1979-02-27 Affiliated Medical Research Pyridone n-substituee; methode generale de synthese des pyridones
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
CA2161648A1 (fr) * 1993-05-07 1994-11-24 Solomon B. Margolin Compositions et methodes pour la preparation et la prevention de lesions fibreuses
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
CA2214531C (fr) * 1995-03-03 2009-01-20 Solomon B. Margolin Traitement des troubles provoques par les facteurs de croissance a cytokine
CA2232191C (fr) * 1995-09-19 2011-03-15 Solomon B. Margolin Inhibition du facteur alpha de necrose tumorale

Also Published As

Publication number Publication date
CA2253919A1 (fr) 1997-11-13
AU725637B2 (en) 2000-10-19
WO1997041830A1 (fr) 1997-11-13
JP2000510467A (ja) 2000-08-15
NO985197L (no) 1998-11-06
EP0902680A4 (fr) 2000-04-19
AU2751997A (en) 1997-11-26
NO985197D0 (no) 1998-11-06
US5716632A (en) 1998-02-10
EP0902680A1 (fr) 1999-03-24
TR199802273T2 (xx) 2000-11-21
KR20000010676A (ko) 2000-02-25
IL126891A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
ZA974041B (en) Preparation and prevention of fibrotic lesions
IL120124A0 (en) Heteroaryl-oxazolidinones their preparation and use
AP9801369A0 (en) Dispersible macromole-cule compositions and methods for their preparation and use
AU4895697A (en) Nontoxic extract of larrea tridentata and method of making the same
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
IL117609A (en) Combined audio and modem interface unit
GB9611180D0 (en) Treatment of vascular lesions
AU2054797A (en) Isolated human herpesvirus type 8 sequences and uses thereof
AU3118297A (en) Sok-1 and methods of use
PL329122A1 (en) Pesticidal compositions of ciprodinyl and myclobutanil or yprodione
CY2590B2 (en) Preparation of 1-butyl-4-piperidinylmethylamine
GB2309887B (en) Structure of percolator
PL328334A1 (en) Preparation and application thereof
IL118404A0 (en) Enzyme degrading rhamnogalacturonane II its preparation and use
GB9623539D0 (en) Enzymes and their use
AU3762397A (en) Treatment and prevention of helicobacter infection
AU2727097A (en) Prevention of dye-bleeding and transfer during laundering
ZA9711669B (en) Cyanophosphorus compounds and their preparation
AU5955698A (en) Preparation of modified cokes and/or blacks
EG21548A (en) Elimination and inhibition of bivalve mollusk attachment
AU7364596A (en) Human b-cell translocation genes-2 and 3
GB9611869D0 (en) Preparation of fluoroketones
ZA9710857B (en) Novel calpains their preparation and use
TW306233U (en) Additional improvement of kettle structure
TW371471U (en) Bow-funnel and EQUIP of smoke-clearing